Case-Based Learning on Chronic Inflammatory Dermatoses With Barrier Function Failure

Abstract

Chronic inflammatory dermatoses characterized by barrier function failure, such as atopic dermatitis, psoriasis, and chronic hand eczema, pose significant diagnostic and therapeutic challenges in clinical practice. Case-based learning provides a practical framework for understanding the multifactorial etiology, pathophysiology, and management strategies informed by current evidence and guidelines. This review synthesizes key clinical presentations, risk factors, mechanisms of barrier dysfunction, and contemporary management—including emerging therapies—offering actionable insights for healthcare professionals.

Introduction

Chronic inflammatory dermatoses with impaired barrier function represent a spectrum of disorders marked by persistent skin inflammation, relapsing courses, and significant morbidity. These conditions, notably atopic dermatitis (AD), psoriasis, and chronic hand eczema, are associated with genetic, immunologic, and environmental factors leading to barrier dysfunction. A case-based approach allows clinicians to contextualize core concepts, integrate guidelines, and tailor interventions. This article presents an updated, evidence-based review to guide diagnosis and management, emphasizing the importance of barrier integrity in disease pathogenesis and outcomes.

Epidemiology / Disease Burden

Chronic inflammatory dermatoses are prevalent worldwide, affecting up to 20% of children (atopic dermatitis) and 2–3% of adults (psoriasis). Chronic hand eczema impacts 5–10% of the general population, particularly among healthcare and manual labor workers. These conditions contribute to substantial healthcare utilization, reduced quality of life, and psychological distress. The global burden is amplified by recurrent flares, comorbidities (e.g., asthma, metabolic syndrome), and occupational limitations. Recent population-based studies underscore the increasing incidence, especially in urbanized regions, attributed to environmental and lifestyle factors.

Pathophysiology

Barrier function failure in chronic dermatoses is multifactorial. In AD, filaggrin gene mutations impair the stratum corneum, increasing transepidermal water loss (TEWL) and antigen penetration, which perpetuates Th2-mediated inflammation. Psoriasis exhibits dysregulation of keratinocyte proliferation and differentiation, driven by Th17/IL-23 axis activation, compromising barrier repair and antimicrobial defense. Chronic hand eczema involves cumulative irritant and allergic insults, disrupting lipid bilayers and innate immunity. Microbiome alterations, including Staphylococcus aureus colonization, further exacerbate barrier dysfunction and inflammation across these disorders.

Risk Factors

Genetic predisposition (e.g., FLG mutations, HLA-Cw6 allele), personal or family history of atopy or psoriasis, and environmental exposures (detergents, allergens, climatic extremes) are key risk factors. Occupational exposures, particularly in healthcare, food, and cleaning industries, heighten risk for hand eczema. Infections, psychological stress, and comorbidities (e.g., obesity, metabolic syndrome) modulate disease severity and barrier integrity. Understanding individual risk profiles is critical for risk stratification and prevention strategies.

Clinical Features

Patients commonly present with chronic or relapsing eczematous or psoriasiform plaques, pruritus, xerosis, fissuring, and lichenification. In AD, flexural involvement and early onset predominate, often accompanied by allergic comorbidities. Psoriasis lesions are classically well-demarcated, erythematous with silvery scales, affecting extensor surfaces and scalp. Chronic hand eczema features vesiculation, scaling, and fissures, frequently localized to the dorsal hands and fingers. Secondary infections, sleep disturbance, and psychological distress are frequent complications impacting daily function.

Diagnosis

Diagnosis is clinical, supported by history, morphology, and distribution. Diagnostic criteria (Hanifin-Rajka for AD, CASPAR for psoriatic arthritis) and validated scoring systems (SCORAD, PASI) aid assessment. Patch testing identifies contact allergens in hand eczema. Skin biopsy may be warranted for atypical cases or diagnostic uncertainty. Emerging non-invasive tools, such as TEWL measurement and confocal microscopy, offer quantitative assessment of barrier function. Exclusion of mimickers (e.g., cutaneous T-cell lymphoma, tinea) is essential.

Treatment & Management

Restoration of barrier integrity is foundational. Regular use of emollients and avoidance of triggers are universally recommended. Topical corticosteroids and calcineurin inhibitors are first-line for acute inflammation. For moderate-to-severe cases, phototherapy and systemic immunomodulators (methotrexate, cyclosporine, azathioprine) are considered. Antimicrobial agents are indicated for secondary infection. In hand eczema, protective measures (gloves, barrier creams) and allergen avoidance are key. Patient education and adherence monitoring enhance outcomes.

Recent Advances / Emerging Therapies

Biologics and targeted small molecules have transformed care for refractory cases. Dupilumab (anti-IL-4Rα) is effective for moderate-to-severe AD, reducing inflammation and restoring barrier function. Psoriasis management has advanced with IL-17 and IL-23 inhibitors (secukinumab, guselkumab), offering high efficacy and favorable safety. Janus kinase (JAK) inhibitors (e.g., upadacitinib, abrocitinib) demonstrate rapid efficacy in AD and are being explored in other dermatoses. Novel barrier-enhancing agents, microbiome-directed therapies, and personalized interventions represent ongoing research frontiers.

Guideline Recommendations

International guidelines (AAD, EADV, NICE) emphasize individualized care, prioritizing barrier restoration, anti-inflammatory therapy, and trigger avoidance. Early intervention, patient education, and multidisciplinary collaboration are recommended. Biologics and systemic therapies are reserved for severe or refractory cases, following assessment for comorbidities and contraindications. Regular monitoring for adverse effects, infection risk, and psychosocial impact is essential. Shared decision-making and patient-centered approaches are advocated to optimize adherence and quality of life.

Conclusion

Chronic inflammatory dermatoses with barrier function failure require a nuanced, evidence-based approach integrating pathophysiological insights, risk stratification, and guideline-directed management. Advances in immunologic understanding and therapeutic options have expanded the armamentarium, offering hope for improved outcomes. Case-based learning fosters deeper clinical reasoning, helping clinicians translate evolving science into practice and address the unmet needs of this patient population.